📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-08 15:23
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
8 announcements match the current filters (relevance ≥ 5).
Medi Caps Ltd Announces Resignation of Chairperson and Appointment of New CFO
Medi Caps Ltd has reported significant leadership changes, including the resignation of its Chairperson, Mr. Ramesh Chandra Mittal, effective August 6, 2026. Mr. Akshit Garg has been appointed as the new Chief Financial Officer (CFO) effective August 7, 2026, filling the vacancy left by Mr. Hemant Sethi who resigned in June 2026. These changes occur as the company faces financial pressure, with TTM revenue declining to ₹12 Cr from ₹25.48 Cr in FY25 and a TTM net loss of ₹3 Cr. The board has also updated its authorized personnel for determining material disclosures under SEBI regulations.
Confidence: HIGH
What changedThe company has replaced its CFO and seen the exit of its Chairperson within a two-month window.
Why it mattersLeadership transitions at the Chairperson and CFO levels are critical for a micro-cap company currently reporting operating losses and significant revenue contraction.
CFO Appointment Date: 07th August 2026Chairperson Resignation Date: 06th August 2026TTM Revenue: ₹12 CrTTM Net Profit: ₹-3 CrMarket Cap: ₹34 Cr
📅 Short termThe stock may remain range-bound as the market processes the exit of the Chairperson and waits for the new management's first quarterly performance.
📈 Long termThe structural impact is significant given the small scale of the company; long-term stability depends on the new leadership's ability to return the company to profitability.
⚠ Risk flags
- High management turnover (CFO and Chairperson within 60 days)
- Significant revenue decline (FY26 ₹12.45 Cr vs FY25 ₹25.48 Cr)
- Persistent operating losses
Key Highlights
Mr. Ramesh Chandra Mittal resigned as Chairperson and Non-Executive Director effective August 6, 2026
Mr. Akshit Garg appointed as Chief Financial Officer (CFO) effective August 7, 2026
Previous CFO Mr. Hemant Sethi resigned from the position effective June 6, 2026
Company reported a TTM revenue of ₹12 Cr against a market cap of ₹34 Cr
Authorization for materiality determination now rests with Alok K Garg (CMD), Akshit Garg (CFO), and Abhishek Kumar (CS)
👀 What to Watch
Investors should monitor the new CFO's impact on financial discipline and the company's ability to arrest the ~50% year-on-year revenue decline seen in FY26.
Medi Caps Ltd Appoints New CFO and Whole Time Director; Re-appoints CMD for 3 Years
Medi Caps Ltd has announced a significant management restructuring, re-appointing Mr. Alok K. Garg as Chairman and Managing Director for a three-year term starting September 1, 2026. The board also appointed Mr. Akshit Garg as the new Chief Financial Officer and Mrs. Saloni Garg as a Whole Time Woman Director, effective August 7, 2026. These appointments come as the company faces financial headwinds, with TTM revenue declining to Rs 12 crore and operating margins at -75.5%. The leadership remains concentrated within the promoter family, as the CMD is the father-in-law of the new Whole Time Director.
Confidence: HIGH
What changedThe company has formalized its top leadership for the next three years, filling the CFO and Whole Time Director roles while extending the CMD's tenure.
Why it mattersLeadership continuity is established, but the high concentration of family members in key roles (CMD, CFO, WTD) in a micro-cap with declining revenues (FY25: Rs 25.48 Cr to FY26: Rs 12.45 Cr) warrants close observation of corporate governance and performance.
CMD Re-appointment Term: 3 yearsCFO Effective Date: 07th August, 2026TTM Revenue: Rs 12 CrMarket Cap: Rs 33 CrOperating Profit Margin (FY26): -75.66%
📅 Short termThe market is likely to view these internal and family-based appointments as routine for a micro-cap, with little immediate impact on the stock price.
📈 Long termThe structural challenge remains the company's ability to return to profitability and scale revenue, which halved between FY25 and FY26.
⚠ Risk flags
- Related-party management concentration
- Significant operating losses
- Declining annual revenue trend
Key Highlights
Re-appointment of Mr. Alok K. Garg as CMD for a 3-year term from September 2026 to August 2029
Appointment of Mr. Akshit Garg as CFO and KMP effective August 7, 2026
Appointment of Mrs. Saloni Garg as Whole Time Woman Director for a 3-year term
Company reported a TTM net loss of Rs 3 crore on a revenue base of Rs 12 crore
Promoter holding remains stable at 51.44% as of June 2026
👀 What to Watch
Investors should monitor whether this leadership team can execute a turnaround, specifically focusing on improving the operating profit margin which stood at -75.66% for FY26.
Medi Caps Ltd Appoints New CFO and Re-appoints MD for 3-Year Term
Medi Caps Ltd has announced a significant leadership reshuffle, re-appointing Mr. Alok K. Garg as Chairman and Managing Director for a three-year term starting September 1, 2026. The board also appointed Mr. Akshit Garg as the new CFO and Mrs. Saloni Garg as a Whole Time Woman Director, effective August 7, 2026. These changes occur as the company faces financial stress, with TTM revenue declining to Rs 12 Cr and operating margins at -75.5%. The appointments consolidate family management, as Mrs. Saloni Garg is the daughter-in-law of the MD.
Confidence: HIGH
What changedThe company has formalized its top leadership for the next three years, including a new CFO and a new Whole Time Woman Director.
Why it mattersFor a micro-cap company with a Rs 33 Cr market cap and ongoing losses, leadership stability and financial oversight from a dedicated CFO are essential for any potential turnaround.
MD Re-appointment Term: 3 yearsCFO Experience: 8+ yearsTTM Revenue: Rs 12 CrNet Worth: Rs 112 CrMarket Cap: Rs 33 Cr
📅 Short termThe market is likely to remain neutral as these are internal/family management appointments and do not immediately address the operational losses.
📈 Long termThe long-term outlook depends on the new management's ability to pivot the business, given that current operations are generating negative ROCE of -2.6%.
⚠ Risk flags
- Related-party appointments (MD's daughter-in-law)
- Severe operating losses (OPM -75.5%)
- Significant year-on-year revenue contraction
Key Highlights
Re-appointment of Alok K. Garg as Chairman and MD for a 3-year term (2026-2029)
Appointment of Akshit Garg as CFO and KMP effective August 7, 2026
Appointment of Saloni Garg as Whole Time Woman Director for a 3-year term
Company reported a significant revenue drop from Rs 25.48 Cr in FY25 to Rs 12.45 Cr in FY26
Operating profit margin remains deeply negative at -75.5% for the trailing twelve months
👀 What to Watch
Investors should monitor whether this leadership team can arrest the 50% year-on-year revenue decline and utilize the company's substantial net worth of Rs 112 Cr to generate positive ROCE.
Medi Caps Re-appoints Alok K. Garg as CMD; Appoints New CFO and Woman Director
Medi Caps Ltd has announced a leadership reshuffle, re-appointing Mr. Alok K. Garg as Chairman cum Managing Director for a three-year term effective September 1, 2026. The board also appointed Mr. Akshit Garg as CFO and Mrs. Saloni Garg (daughter-in-law of the CMD) as a Whole Time Woman Director, both effective August 7, 2026. These changes come as the company faces financial stress, with a TTM revenue of just Rs 12 cr and an operating margin of -75.5%. The appointments are subject to shareholder approval at the upcoming 43rd Annual General Meeting.
Confidence: HIGH
What changedThe company has formalized its top leadership structure for the next three years, including the re-appointment of the CMD and the induction of a new CFO and a Woman Director from the promoter family.
Why it mattersFor a micro-cap company with significant operating losses, leadership stability and the financial oversight of a new CFO are critical for any potential turnaround or stabilization of the business.
CMD Tenure: 3 YearsTTM Revenue: Rs 12 CrOperating Profit Margin: -75.5%Market Cap: Rs 33 CrCFO Experience: 8+ Years
📅 Short termThe market is likely to react neutrally as these are largely internal promoter-led appointments; focus will remain on the next quarterly earnings to see if management can reduce losses.
📈 Long termThe structural significance lies in the concentration of management within the Garg family; long-term value will depend on their ability to scale the business beyond the current Rs 12 cr revenue base.
⚠ Risk flags
- Related-party management (CMD's daughter-in-law appointed as Director)
- Persistent operating losses
- Small scale of operations relative to net worth
Key Highlights
Re-appointment of Mr. Alok K. Garg as CMD for a 3-year term from September 1, 2026, to August 31, 2029
Appointment of Mr. Akshit Garg as CFO and KMP effective August 7, 2026, citing 8 years of experience in finance
Appointment of Mrs. Saloni Garg as Whole Time Woman Director for a 3-year term starting August 7, 2026
Company reported a TTM net loss of Rs 3 cr against a market capitalization of Rs 33 cr
Promoter holding remains stable at 51.44% as of June 2026
👀 What to Watch
Investors should monitor the upcoming 43rd AGM for shareholder approval of these appointments and watch for any strategic shifts aimed at correcting the -75.5% operating margin.
Medi Caps Ltd Appoints New CFO and Whole Time Director; Re-appoints CMD for 3 Years
Medi Caps Ltd has announced a leadership reshuffle, appointing Mr. Akshit Garg as Chief Financial Officer (CFO) effective August 7, 2026. The board also re-appointed Mr. Alok K. Garg as Chairman and Managing Director for a three-year term starting September 1, 2026. Additionally, Mrs. Saloni Garg has been appointed as a Whole Time Woman Director for three years. These changes occur as the company faces financial challenges, with TTM revenue of Rs 12 crore and a net loss of Rs 3 crore.
Confidence: HIGH
What changedThe company has filled the CFO position and added a new Whole Time Director while extending the tenure of the current Managing Director.
Why it mattersFor a micro-cap company with a Rs 33 Cr market cap and ongoing losses, the effectiveness of the CFO and leadership team is critical for financial stabilization and potential turnaround.
CMD Tenure: 3 yearsCFO Experience: 8+ yearsTTM Revenue: Rs 12 CrTTM PAT: Rs -3 CrOperating Profit Margin (FY26): -75.66%
📅 Short termThe management changes are unlikely to impact the stock price significantly in the short term given the company's current loss-making status.
📈 Long termThe long-term outlook depends on the new management's ability to improve margins and recover revenue, which halved between FY25 and FY26.
⚠ Risk flags
- Related-party appointments (CMD is father-in-law to the new Woman Director)
- Significant financial distress (negative OPM and PAT)
- Small market capitalization (Rs 33 Cr) leading to low liquidity
Key Highlights
Appointment of Mr. Akshit Garg as CFO and KMP effective August 7, 2026.
Re-appointment of Mr. Alok K. Garg as CMD for a 3-year term ending August 31, 2029.
Appointment of Mrs. Saloni Garg as Whole Time Woman Director for a 3-year term.
Mr. Akshit Garg brings over 8 years of experience in Finance, Marketing, and Real Estate.
Mrs. Saloni Garg is the daughter-in-law of the CMD, Mr. Alok K. Garg.
👀 What to Watch
Investors should monitor if the new management team can address the company's significant operating losses (OPM of -75.5%) and the 51% decline in annual revenue from FY25 to FY26.
Medi Caps Reports Q1 Net Loss of ₹2.23 Cr; Appoints New CFO and Director
Medi Caps Ltd reported a consolidated net loss of ₹2.23 Cr for the quarter ended June 30, 2026, narrowing from a loss of ₹3.49 Cr in the same period last year. Consolidated revenue remained stagnant at ₹2.79 Cr, with the Pharma division contributing 96% of the total. The company also announced a management reshuffle, appointing Akshit Garg as CFO and Saloni Garg as a Whole Time Director. Despite a substantial net worth of ₹112 Cr, the company continues to face operational challenges with negative segment results across both Pharma and Real Estate divisions.
Confidence: HIGH
What changedThe company has returned to a loss-making position after a brief profitable quarter in March 2026 and has restructured its senior management team with new CFO and Director appointments.
Why it mattersWhile the stock trades at a deep discount to its book value (P/B 0.3), the persistent operational losses and low revenue-to-net-worth ratio (annualized ~10%) indicate significant underutilization of assets.
Consolidated Revenue: ₹2.79 CrConsolidated Net Loss: ₹2.23 CrPharma Segment Revenue: ₹2.68 CrReal Estate Segment Revenue: ₹0.10 CrNet Worth: ₹112 CrTTM Revenue vs Net Worth: 10.7%
📅 Short termThe stock is likely to remain under pressure due to continued operational losses and a lack of growth in the core pharma segment.
📈 Long termThe long-term outlook depends on the company's ability to turn around its pharma operations; currently, the business remains structurally weak despite a strong balance sheet.
⚠ Risk flags
- Persistent operational losses
- Low asset turnover
- Concentration of management roles within the promoter family
Key Highlights
Consolidated net loss narrowed to ₹2.23 Cr from ₹3.49 Cr in the year-ago quarter.
Pharma division revenue stood at ₹2.68 Cr, accounting for nearly all operational income.
Real Estate division revenue dropped to ₹0.10 Cr from ₹0.53 Cr in the preceding March quarter.
Akshit Garg appointed as Chief Financial Officer (CFO) effective August 7, 2026.
Alok K. Garg re-appointed as Chairman and Managing Director for a 3-year term starting September 2026.
👀 What to Watch
Investors should monitor the company's ability to scale its Pharma subsidiary, Medgel Private Limited, and the pace of inventory liquidation in its Real Estate project (Medi-caps Business Park) to achieve break-even.
Medi Caps Q1 Net Loss Narrows to 2.23 Cr; Appoints New CFO and Whole Time Director
Medi Caps reported a consolidated net loss of 2.23 Cr for Q1 FY27, showing improvement from a 3.49 Cr loss in the year-ago period. Consolidated revenue for the quarter stood at 2.79 Cr, with the Pharma division contributing 96% of the total. The company also announced a management reshuffle, appointing Akshit Garg as CFO and Saloni Garg as a Whole Time Director. Despite the narrowing loss, both the Pharma and Real Estate segments remain loss-making at the operational level.
Confidence: HIGH
What changedThe company reported its first-quarter financial results for FY27 and restructured its senior management team, including the appointment of a new CFO and a Whole Time Woman Director.
Why it mattersThe company continues to operate at a loss despite having a significant net worth of 112 Cr relative to its 34 Cr market cap. The management changes indicate a consolidation of leadership within the promoter family.
Q1 Consolidated Revenue: 2.79 CrQ1 Consolidated Net Loss: 2.23 CrPharma Segment Loss: 1.64 CrMarket Cap to Net Worth: ~0.3xAGM Date: 22.09.2026
📅 Short termThe narrowing of losses is a slight positive, but the low revenue scale and continued operational losses are likely to keep the stock range-bound in the near term.
📈 Long termThe company's long-term viability depends on scaling its Pharma operations or successfully pivoting its Real Estate division, as current revenues are insufficient to cover employee and administrative costs.
⚠ Risk flags
- Persistent operational losses
- Small revenue scale relative to asset base
- High concentration of management roles within the promoter family
Key Highlights
Consolidated net loss narrowed to 2.23 Cr in Q1 FY27 from 3.49 Cr in Q1 FY26
Pharma division revenue remained steady at 2.68 Cr compared to 2.69 Cr YoY
Real Estate segment generated minimal revenue of 10.49 Lacs from the sale of shops
Akshit Garg appointed as Chief Financial Officer (CFO) effective August 7, 2026
Alok K. Garg re-appointed as Managing Director for a 3-year term starting September 2026
👀 What to Watch
Monitor the Pharma division's ability to reach break-even, as it currently reports a segment loss of 1.64 Cr. Investors should also track the 43rd AGM on September 22, 2026, for updates on the Real Estate monetization strategy.
Resignation of Chairman Ramesh Chandra Mittal and Director Kusum Mittal effective Aug 6, 2026
Medi Caps Ltd has announced the resignation of its Chairman, Mr. Ramesh Chandra Mittal, and Non-Executive Director, Mrs. Kusum Mittal, effective August 6, 2026. Both directors cited personal health concerns as the reason for their departure. This leadership change occurs as the company faces significant financial headwinds, with TTM revenue falling to Rs 12 Cr from Rs 25.48 Cr in FY25. The company is currently loss-making with a TTM PAT of Rs -3 Cr and a highly negative operating margin of -75.5%.
Confidence: HIGH
What changedThe Chairman and one Non-Executive Director have resigned from the board due to personal health reasons.
Why it mattersWhile the roles are non-executive, the departure of the Chairman from a promoter-led micro-cap (Rs 34 Cr market cap) could signal a transition phase or a potential change in governance during a period of operational stress.
Effective Date: 06th August, 2026Market Cap: Rs 34 CrTTM Revenue: Rs 12 CrTTM Operating Margin: -75.5%Promoter Holding: 51.44%
📅 Short termNeutral; the market is likely to wait for the announcement of a successor before reacting, given the low liquidity of the stock.
📈 Long termLimited structural significance unless the leadership change leads to a reversal of the current revenue contraction and negative margins.
⚠ Risk flags
- Leadership transition during financial losses
- Significant revenue decline (50% YoY)
- Negative operating margins
Key Highlights
Resignation of Chairman Mr. Ramesh Chandra Mittal effective from the close of business hours on 06th August, 2026.
Resignation of Non-Executive Director Mrs. Kusum Mittal effective from the close of business hours on 06th August, 2026.
Company TTM revenue of Rs 12 Cr represents a sharp decline from FY25 revenue of Rs 25.48 Cr.
Operating Profit Margin (OPM) remains deeply negative at -75.5% for the trailing twelve months.
Promoter holding remains stable at 51.44% as of June 2026.
👀 What to Watch
Investors should monitor the upcoming Board Meeting for the appointment of a new Chairperson and any strategic updates regarding the company's turnaround plan given the 50% year-on-year revenue decline.
